HilleVax Inc. has set terms for its initial public offering, in which the Massachusetts-based biopharmaceutical company that focuses on developing novel vaccines looks to raise up to $185.3 million. The company said it is offering 10.29 million shares in the IPO, which is expected to price between $16 and $18 a share. With 30.19 million shares expected to be outstanding after the IPO, the expected pricing range could value the company at up to $543.45 million. HilleVax's stock is expected to list on the Nasdaq under the ticker symbol "HLVX."